Biomotion Sciences

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Silexion Therapeutics Corp. engages in the discovery and development of treatments for KRAS-driven cancers. The company is headquartered in Modiin, Israel.

Amgen

LONDON--(BUSINESS WIRE)---- $AMGN #biotech--PESG Research Releases an Market Update Report on Silexion Therapeutics (NASDAQ: SLXN). The precision oncology sector has rapidly evolved into one of the most dynamic areas of cancer treatment innovation. Among the key players pioneering novel approaches is Silexion Therapeutics, a clinical-stage biotechnology company focused on RNA interference (RNAi) therapies for KRAS-driven cancers—one of the most prevalent and historically “undruggable” oncogenic drivers. Silexion'.

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

Trading on split-adjusted basis will begin at market open on November 29, 2024. This adjustment is expected to help Silexion comply with NASDAQ requirements, enhance its market position, and support its strategic growth initiatives Trading on split-adjusted basis will begin at market open on November 29, 2024. This adjustment is expected to help Silexion comply with NASDAQ requirements, enhance its market position, and support its strategic growth initiatives

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that the Company's management will be attending and presenting at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference taking place December 3-4, 2024, in Boca Raton, Florida.

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

GRAND CAYMAN, Cayman Island--(BUSINESS WIRE)---- $SLXN #BioTech--Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced new preclinical findings for SIL-204, its second-generation siRNA candidate, following the optimization of its extended-release formulation. These latest findings demonstrate that the latest SIL-204-microparticle formulation can inhibit the growth and induce necrosis.

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Silexion Therapeutics Corp. SLXN stock is up more than 21.72% in pre-market trading Tuesday after the company revealed new findings from a Phase 2 trial for its first-generation product, LODER.

Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise

GRAND CAYMAN, Cayman Island--(BUSINESS WIRE)---- $SLXN #BioTech--Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced significant new findings from its Phase 2 trial of LODER™ in patients with non-resectable locally advanced pancreatic cancer (LAPC) which bear the KRAS G12D or G12V mutation (approximately 70% of pancreatic cancer patients). Overall the updated analysis reveals a 56%.

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

Moringa Acquisition Corp

LONDON--(BUSINESS WIRE)---- $MACA #KRAS--Silexion Therapeutics (NASDAQ: SLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference (RNAi) therapies for KRAS-driven cancers. As a recently de-SPACed company following its merger with Moringa Acquisition Corp (NASDAQ: MACA), Silexion presents an interesting opportunity in the rapidly growing field of targeted cancer treatments, particularly in addressing the challenges of pancreati.

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

GRAND CAYMAN, Cayman Island, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company today announced that Company management will be attending and presenting at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY.

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

The combined company's shares and warrants are expected to begin trading on Nasdaq under the tickers “SLXN” and “SLXNW”, respectively on August 16, 2024 The combined company's shares and warrants are expected to begin trading on Nasdaq under the tickers “SLXN” and “SLXNW”, respectively on August 16, 2024

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

News for Biomotion Sciences Stock (SLXN)